Colorectal cancer (CRC) belongs to the most common cancers. The liver is a predominant site of CRC dissemination. Novel biomarkers for predicting the survival of CRC patients with liver metastases (CLM) undergoing metastasectomy are needed. We examined KRAS mutated circulating cell-free tumor DNA (ctDNA) in CLM patients as a prognostic biomarker, independently or in combination with carcinoembryonic antigen (CEA). Thereby, a total of 71 CLM were retrospectively analyzed. Seven KRAS G12/G13 mutations was analyzed by a ddPCR™ KRAS G12/G13 Screening Kit on QX200 Droplet Digital PCR System (Bio-Rad Laboratories, Hercules, CA, USA) in liver metastasis tissue and preoperative and postoperative plasma samples. CEA were determined by an ACCESS CEA assay with the UniCel DxI 800 Instrument (Beckman Coulter, Brea, CA, USA). Tissue KRAS positive liver metastases was detected in 33 of 69 patients (47.8%). Preoperative plasma samples were available in 30 patients and 11 (36.7%) were KRAS positive. The agreement between plasma- and tissue-based KRAS mutation status was 75.9% (22 in 29; kappa 0.529). Patients with high compared to low levels of preoperative plasma KRAS fractional abundance (cut-off 3.33%) experienced shorter overall survival (OS 647 vs. 1392 days, p = 0.003). The combination of high preoperative KRAS fractional abundance and high CEA (cut-off 3.33% and 4.9 µg/L, resp.) best predicted shorter OS (HR 13.638, 95%CI 1.567-118.725) in multivariate analysis also (OS HR 44.877, 95%CI 1.59-1266.479; covariates: extend of liver resection, biological treatment). KRAS mutations are detectable and quantifiable in preoperative plasma cell-free DNA, incompletely overlapping with tissue biopsy. KRAS mutated ctDNA is a prognostic factor for CLM patients undergoing liver metastasectomy. The best prognostic value can be reached by a combination of ctDNA and tumor marker CEA.

Department of Biology Charles University Faculty of Medicine in Pilsen alej Svobody 76 32300 Pilsen Czech Republic

Department of Histology and Embryology and Biomedical Center Charles University Faculty of Medicine in Pilsen Karlovarska 48 30166 Pilsen Czech Republic

Department of Surgery University Hospital in Pilsen E Beneše 13 30599 Pilsen Czech Republic

Laboratory of Immunoanalysis University Hospital in Pilsen E Benese 13 30599 Pilsen Czech Republic

Zobrazit více v PubMed

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Engstrand J., Nilsson H., Strömberg C., Jonas E., Freedman J. Colorectal cancer liver metastases—A population-based study on incidence, management and survival. BMC Cancer. 2018;18:78. doi: 10.1186/s12885-017-3925-x. PubMed DOI PMC

Golubnitschaja O., Polivka J., Yeghiazaryan K., Berliner L. Liquid biopsy and multiparametric analysis in management of liver malignancies: New concepts of the patient stratification and prognostic approach. EPMA J. 2018;9:271–285. doi: 10.1007/s13167-018-0146-6. PubMed DOI PMC

Kow A.W.C. Hepatic metastasis from colorectal cancer. J. Gastrointest. Oncol. 2019;10:1274–1298. doi: 10.21037/jgo.2019.08.06. PubMed DOI PMC

Rosty C., Young J.P., Walsh M.D., Clendenning M., Walters R.J., Pearson S., Pavluk E., Nagler B., Pakenas D., Jass J.R., et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod. Pathol. 2013;26:825–834. doi: 10.1038/modpathol.2012.240. PubMed DOI

Normanno N., Tejpar S., Morgillo F., De Luca A., Van Cutsem E., Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 2009;6:519–527. doi: 10.1038/nrclinonc.2009.111. PubMed DOI

Malumbres M., Barbacid M. RAS oncogenes: The first 30 years. Nat. Rev. Cancer. 2003;3:459–465. doi: 10.1038/nrc1097. PubMed DOI

Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol. 1994;86:774–779. doi: 10.1111/j.1365-2141.1994.tb04828.x. PubMed DOI

Sorenson G.D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 2000;6:2129–2137. doi: 10.1111/j.1749-6632.2000.tb06582.x. PubMed DOI

Sorenson G.D., Pribish D.M., Valone F.H., Memoli V.A., Bzik D.J., Yao S.L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomark. Prev. 1994;3:67–71. PubMed

Karapetis C.S., Khambata-Ford S., Jonker D.J., O’Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008;359:1757–1765. doi: 10.1056/NEJMoa0804385. PubMed DOI

Douillard J.-Y., Oliner K.S., Siena S., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013;369:1023–1034. doi: 10.1056/NEJMoa1305275. PubMed DOI

Peeters M., Oliner K.S., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., André T., Chan E., Lordick F., et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin. Cancer Res. 2015;21:5469–5479. doi: 10.1158/1078-0432.CCR-15-0526. PubMed DOI

Van Cutsem E., Lenz H.-J., Köhne C.-H., Heinemann V., Tejpar S., Melezínek I., Beier F., Stroh C., Rougier P., van Krieken J.H., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 2015;33:692–700. doi: 10.1200/JCO.2014.59.4812. PubMed DOI

Allegra C.J., Rumble R.B., Hamilton S.R., Mangu P.B., Roach N., Hantel A., Schilsky R.L. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J. Clin. Oncol. 2016;34:179–185. doi: 10.1200/JCO.2015.63.9674. PubMed DOI

Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J.H., Aderka D., Aranda Aguilar E., Bardelli A., Benson A., Bodoky G., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016;27:1386–1422. doi: 10.1093/annonc/mdw235. PubMed DOI

Schmiegel W., Scott R.J., Dooley S., Lewis W., Meldrum C.J., Pockney P., Draganic B., Smith S., Hewitt C., Philimore H., et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: Concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol. Oncol. 2017;11:208–219. doi: 10.1002/1878-0261.12023. PubMed DOI PMC

García-Foncillas J., Tabernero J., Élez E., Aranda E., Benavides M., Camps C., Jantus-Lewintre E., López R., Muinelo-Romay L., Montagut C., et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br. J. Cancer. 2018;119:1464–1470. doi: 10.1038/s41416-018-0293-5. PubMed DOI PMC

Lecomte T., Berger A., Zinzindohoué F., Micard S., Landi B., Blons H., Beaune P., Cugnenc P.-H., Laurent-Puig P. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer. 2002;100:542–548. doi: 10.1002/ijc.10526. PubMed DOI

Lindforss U., Zetterquist H., Papadogiannakis N., Olivecrona H. Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res. 2005;25:657–661. PubMed

Trevisiol C., Di Fabio F., Nascimbeni R., Peloso L., Salbe C., Ferruzzi E., Salerni B., Gion M. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int. J. Biol. Markers. 2006;21:223–228. doi: 10.1177/172460080602100405. PubMed DOI

Spindler K.-L.G., Pallisgaard N., Vogelius I., Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin. Cancer Res. 2012;18:1177–1185. doi: 10.1158/1078-0432.CCR-11-0564. PubMed DOI

Bai Y., Liu X., Wang Y., Ge F., Zhao C., Fu Y., Lin L., Xu J. Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2013;35:666–671. PubMed

Spindler K.G., Appelt A.L., Pallisgaard N., Andersen R.F., Jakobsen A. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br. J. Cancer. 2013;109:3067–3072. doi: 10.1038/bjc.2013.633. PubMed DOI PMC

Xu J.-M., Liu X.-J., Ge F.-J., Lin L., Wang Y., Sharma M.R., Liu Z.-Y., Tommasi S., Paradiso A. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J. Exp. Clin. Cancer Res. 2014;33:104. doi: 10.1186/s13046-014-0104-7. PubMed DOI PMC

Siravegna G., Mussolin B., Buscarino M., Corti G., Cassingena A., Crisafulli G., Ponzetti A., Cremolini C., Amatu A., Lauricella C., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015;21:795–801. doi: 10.1038/nm.3870. PubMed DOI PMC

Spindler K.L.G., Pallisgaard N., Andersen R.F., Brandslund I., Jakobsen A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS ONE. 2015;10:e0108247. doi: 10.1371/journal.pone.0108247. PubMed DOI PMC

El Messaoudi S., Mouliere F., Du Manoir S., Bascoul-Mollevi C., Gillet B., Nouaille M., Fiess C., Crapez E., Bibeau F., Theillet C., et al. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin. Cancer Res. 2016;22:3067–3077. doi: 10.1158/1078-0432.CCR-15-0297. PubMed DOI

Luo H., Shen K., Li B., Li R., Wang Z., Xie Z. Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer. Oncol. Lett. 2020;20:742–750. doi: 10.3892/ol.2020.11633. PubMed DOI PMC

Kang H.Y., Choe E.K., Park K.J., Lee Y. Factors Requiring Adjustment in the Interpretation of Serum Carcinoembryonic Antigen: A Cross-Sectional Study of 18,131 Healthy Nonsmokers. Gastroenterol. Res. Pract. 2017;2017:9858931. doi: 10.1155/2017/9858931. PubMed DOI PMC

Hall C., Clarke L., Pal A., Buchwald P., Eglinton T., Wakeman C., Frizelle F. A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Ann. Coloproctol. 2019;35:294–305. doi: 10.3393/ac.2019.11.13. PubMed DOI PMC

Abdul-Wahid A., Cydzik M., Fischer N.W., Prodeus A., Shively J.E., Martel A., Alminawi S., Ghorab Z., Berinstein N.L., Gariépy J. Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. Int. J. Cancer. 2018;143:1963–1977. doi: 10.1002/ijc.31586. PubMed DOI PMC

Calinescu A., Turcu G., Nedelcu R.I., Brinzea A., Hodorogea A., Antohe M., Diaconu C., Bleotu C., Pirici D., Jilaveanu L.B., et al. On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies. J Immunol. Res. 2018;2018:7169081. doi: 10.1155/2018/7169081. PubMed DOI PMC

Pesta M., Kucera R., Topolcan O., Karlikova M., Houfkova K., Polivka J., Macanova T., Machova I., Slouka D., Kulda V. Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients. Cancers. 2019;11:864. doi: 10.3390/cancers11060864. PubMed DOI PMC

Xie H.-L., Gong Y.-Z., Kuang J.-A., Gao F., Tang S.-Y., Gan J.-L. The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels. Cancer Manag. Res. 2019;11:7499–7511. doi: 10.2147/CMAR.S213580. PubMed DOI PMC

Tan E., Gouvas N., Nicholls R.J., Ziprin P., Xynos E., Tekkis P.P. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol. 2009;18:15–24. doi: 10.1016/j.suronc.2008.05.008. PubMed DOI

Park I.J., Choi G.-S., Lim K.H., Kang B.M., Jun S.H. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: Clinical significance of the preoperative level. Ann. Surg. Oncol. 2009;16:3087–3093. doi: 10.1245/s10434-009-0625-z. PubMed DOI

Nicholson B.D., Shinkins B., Pathiraja I., Roberts N.W., James T.J., Mallett S., Perera R., Primrose J.N., Mant D. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane. Database. Syst. Rev. 2015:CD011134. doi: 10.1002/14651858.CD011134.pub2. PubMed DOI PMC

Knijn N., Mekenkamp L.J.M., Klomp M., Vink-Börger M.E., Tol J., Teerenstra S., Meijer J.W.R., Tebar M., Riemersma S., van Krieken J.H.J.M., et al. KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br. J. Cancer. 2011;104:1020–1026. doi: 10.1038/bjc.2011.26. PubMed DOI PMC

Mardinian K., Okamura R., Kato S., Kurzrock R. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int. J. Cancer. 2020;146:566–576. doi: 10.1002/ijc.32510. PubMed DOI PMC

Cassinotti E., Boni L., Segato S., Rausei S., Marzorati A., Rovera F., Dionigi G., David G., Mangano A., Sambucci D., et al. Free circulating DNA as a biomarker of colorectal cancer. Int. J. Surg. 2013;11(Suppl. 1):S54–S57. doi: 10.1016/S1743-9191(13)60017-5. PubMed DOI

Frattini M., Gallino G., Signoroni S., Balestra D., Battaglia L., Sozzi G., Leo E., Pilotti S., Pierotti M.A. Quantitative analysis of plasma DNA in colorectal cancer patients: A novel prognostic tool. Ann. N. Y. Acad. Sci. 2006;1075:185–190. doi: 10.1196/annals.1368.025. PubMed DOI

Vymetalkova V., Cervena K., Bartu L., Vodicka P. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. Int. J. Mol. Sci. 2018;19 doi: 10.3390/ijms19113356. PubMed DOI PMC

Reinert T., Schøler L.V., Thomsen R., Tobiasen H., Vang S., Nordentoft I., Lamy P., Kannerup A.-S., Mortensen F.V., Stribolt K., et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016;65:625–634. doi: 10.1136/gutjnl-2014-308859. PubMed DOI

Carpinetti P., Donnard E., Bettoni F., Asprino P., Koyama F., Rozanski A., Sabbaga J., Habr-Gama A., Parmigiani R.B., Galante P.A.F., et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015;6:38360–38371. doi: 10.18632/oncotarget.5256. PubMed DOI PMC

Sobin L.H., Gospodarowicz M.K., Wittekind C., editors. TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell; Chichester/West Sussex, UK: Hoboken, NJ, USA: 2011.

Schwartz L.H., Litière S., de Vries E., Ford R., Gwyther S., Mandrekar S., Shankar L., Bogaerts J., Chen A., Dancey J., et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur. J. Cancer. 2016;62:132–137. doi: 10.1016/j.ejca.2016.03.081. PubMed DOI PMC